SCHWARZ PHARMA secures future neurology projects
SCHWARZ PHARMA acquires the worldwide rights to all substances originating from this cooperation that prove effective in the treatment of neuro-degenerative diseases. The project is at the early pre-clinical stage.
"This cooperation adds further attractive potential to our development pipeline. With Professor Feuerstein from the Neurologischen Univer-sitätsklinik, we have gained an excellent partner with a high international reputation in the field of neuropharmacology." said Dr. Dr. Lars Ekman, Executive Board member of SCHWARZ PHARMA AG and responsible for Research and Development. "Our aim is to continue expanding our CNS pipeline. For this reason, we are constantly exam-ining promising opportunities. We are confident that further innovative projects will follow this year."
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.